SCHEMBL17501637

SCHEMBL17501637

COc1ccc(OCCCOS(C)(=O)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
LMNA P02545 3/20 0.50
TSHR P16473 3/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
USP2 O75604 1/20 0.50
MMP9 P14780 1/20 0.50
ALOX15 P16050 1/20 0.50
HPGD P15428 1/20 0.50
ATM Q13315 1/20 0.50
APLNR P35414 1/20 0.47
RECQL P46063 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6277239 0.91 L3MBTL1 (0.49) MAPTL3MBTL1LMNATSHRALDH1A1
SCHEMBL578290 0.91 L3MBTL1 (0.48) MAPTL3MBTL1LMNATSHRALDH1A1
SCHEMBL24041808 0.84 APLNR (0.47) LMNATSHRALDH1A1APLNRMEN1
SCHEMBL10740412 0.84 TSHR (0.48) LMNATSHRALDH1A1KDM4EUSP2
SCHEMBL22749055 0.84 KDM4E (0.48) L3MBTL1LMNATSHRALDH1A1KDM4E
SCHEMBL4741970 0.83 KCNA3 (0.56) L3MBTL1LMNATSHRALDH1A1KDM4E
SCHEMBL24041775 0.83 APLNR (0.50) LMNATSHRALDH1A1ATMAPLNR
SCHEMBL1845841 0.82 APLNR (0.53) L3MBTL1LMNATSHRALDH1A1KDM4E
SCHEMBL8434882 0.82 CA12 (0.61) MAPTL3MBTL1LMNAALDH1A1KDM4E
SCHEMBL1843955 0.81 APLNR (0.51) L3MBTL1LMNATSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10066152-B2 Crosslinkable proppant particulates for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2018-09-04 US claimed
US-20170198208-A1 Crosslinkable Proppant Particulates For Use In Subterranean Formation Operations HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-13 US claimed
WO-2016025002-A1 CROSSLINKABLE PROPPANT PARTICULATES FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2016-02-18 WO claimed
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2025-04-29 US disclosed
EP-3704111-B1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2024-10-09 EP disclosed
CN-111886234-B Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2023-12-15 CN disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed
US-20210387980-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF Université de Montréal (CA) 2021-12-16 US disclosed
US-20210387980-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF Université de Montréal (CA) 2021-12-16 US disclosed
CN-111886234-A Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2020-11-03 CN disclosed
EP-3704111-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF Université de Montréal (CA) 2020-09-09 EP disclosed
US-10066152-B2 Crosslinkable proppant particulates for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2018-09-04 US disclosed
US-20170198208-A1 Crosslinkable Proppant Particulates For Use In Subterranean Formation Operations HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-13 US disclosed
WO-2016025002-A1 CROSSLINKABLE PROPPANT PARTICULATES FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 MAPT 4580/4885L3MBTL1 2679/4885LMNA 1657/4885
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, IDH1 MAPT 4580/4885L3MBTL1 2679/4885LMNA 1657/4885
US-20210387980-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, NUTF2 MAPT 4527/4885L3MBTL1 2246/4885LMNA 1563/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 MAPT 4527/4885L3MBTL1 2246/4885LMNA 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.